When someone is diagnosed with cancer, one of the first questions is simple — what exactly is it? The answer begins with better understanding pathology.

In this episode of NETWise, we examine the central role pathology plays in the diagnosis and management of neuroendocrine cancers — from initial biopsy through classification, grading, and treatment decision-making. Drawing on insights from leading clinicians, pathologists, and researchers, this conversation provides a clear, structured look at how diagnostic precision is established and why it is essential.

A biopsy — analyzed through pathology — is the gold standard for confirming a cancer diagnosis. By examining tumor tissue, pathologists determine not only whether cancer is present, but also define tumor type, differentiation, grade, and key biomarkers that directly inform prognosis and therapeutic strategy.

In neuroendocrine neoplasms, this level of detail is particularly critical. These diseases represent a heterogeneous spectrum, where tumors that may appear similar under the microscope can behave very differently clinically. Distinguishing between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs), as well as accurately assessing measures of tumor growth, can significantly alter treatment pathways and outcomes.

This episode focuses on how those distinctions are made — and why they matter. It explores how pathology moves from a small tissue sample to a precise diagnosis, why interpretation can be complex, and why expert review is often essential, particularly in rare and high-grade disease.

We also address the real-world challenges of pathology interpretation in neuroendocrine cancer, including diagnostic complexity, evolving classification systems, and the importance of second opinions and specialized care.

For patients and caregivers, understanding pathology can help turn a confusing report into meaningful, actionable information. It can clarify what a diagnosis means, why specific treatments are recommended, and when it may be important to seek additional expertise.
It can also help patients ask better questions — about tumor type, grade, and next steps — and better understand the reasoning behind clinical decisions.

And behind every pathology report is a team of specialists looking closely and intentionally at the evidence — working to understand the biology of the disease as clearly as possible so that the next steps are as informed as possible.

Because understanding pathology isn’t just about learning the science.

It’s about turning confusion into clarity.
It’s about knowing what questions to ask.
And it’s about feeling more informed, more prepared, and more empowered in the moments that matter most.

This episode is designed to help bring that clarity — to better understand and demystify pathology, and to make the information behind a diagnosis more accessible, so patients and families can move forward with greater confidence.

Neil Renwick, MD, PhD, FRCPC
Assistant Professor, Department of Pathology & Molecular Medicine, Queen’s University
(SEAMO New Clinician-Scientist Program)

Nancy Joseph, MD, PhD
Professor of Surgical Pathology, University of California, San Francisco (UCSF)

Aman Chauhan, MD
University of California, San Francisco

Jerome Cros, MD, PhD,
Beaujon Hospital, Paris

The post Episode 53: Understanding Pathology appeared first on NETRF.